Wearable Injectors Market (2026 - 2033)

Wearable Injectors Market Summary

The global wearable injectors market size was valued at USD 11.7 billion in 2025 and is projected to grow from USD 13.4 billion in 2026 to USD 37.1 billion by 2033, at a CAGR of 15.6% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 33.2% in 2025. The key factors driving the market include the prevalence of chronic illnesses, the rising geriatric population, and growing concern over needle stick injuries.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

In comparison to other medication delivery methods, wearable injectors are less expensive. Additionally, the desire to reduce healthcare expenditures and the rising demand for continuous monitoring and home-based treatment are anticipated to boost the demand for wearable injectors.

Strong healthcare infrastructure and an increase in lifestyle disorders are some of the factors driving market expansion. However, it is projected that low demand in developing economies and expensive wearable injectors could restrain the market's expansion in the upcoming years. Needle stick injuries (NSIs) constitute the main occupational danger among healthcare workers. According to a WHO study published in 2021, nearly 2 million of the 35 million healthcare professionals worldwide are exposed to occupational injuries each year. The risk of developing infectious diseases including HIV, hepatitis B, and hepatitis C is increased by needle stick injuries.

To learn more about this report, Download Free Sample Report

In addition, reports from the Centers for Disease Control and Prevention (CDC) and European Agency for Safety and Health at Work (EU-OSHA) indicate that healthcare workers in the U.S. & Europe, have about 3,85,000 & 1,000,000 needle stick injuries, respectively. Moreover, according to the World Health Organization (WHO), NSIs result in 16,000, 66,000, and 1,000 instances of HCV, HBV, and HIV respectively, among Health Care Workers (HCWs) annually.

With advanced injector technology, the patient is never in contact with a needle. After attaching the injector and pressing the button, the needle is inserted. The patient is alerted with tactile, audible, and visual indications as soon as the medicine is released, and the needle automatically retracts and locks out, permitting safe and convenient disposal of the device. With the use of wearable injectors, there would be no needle stick injuries as compared to intravenous injectable and parenteral administration.

Wearable injectors increase patient and healthcare worker safety by eliminating the dangers associated with traditional infusion and injection technology, such as drug preparation, needle insertion, covering, and disposal of needles. However, one of the biggest problems emerging and developed countries face is the rise in healthcare costs. Countries strive to provide high-quality and affordable healthcare. Patients can self-administer wearable injectors subcutaneously at home with wearable injectors. It is anticipated to lower the frequency of trips to hospitals or other healthcare facilities, lowering healthcare costs.

Market Dynamics

The wearable injectors market is experiencing significant growth driven by the increasing adoption of biologics, rising prevalence of chronic diseases, and growing demand for patient-centric drug delivery solutions. The market is further supported by the ongoing shift from hospital-based intravenous administration to home-based subcutaneous drug delivery, advancements in large-volume injection technologies, and increasing focus on improving patient convenience, treatment adherence, and healthcare efficiency. Wearable injector systems enable pharmaceutical companies, healthcare providers, and patients to administer complex biologic therapies through controlled and automated subcutaneous drug delivery, reducing the burden associated with frequent clinical visits and conventional infusion procedures. Wearable injectors are widely utilized across a range of therapeutic areas including oncology, autoimmune diseases, cardiovascular disorders, infectious diseases, metabolic disorders, and rare diseases, particularly for therapies requiring the administration of high-volume and high-viscosity biologic drugs. These devices facilitate precise drug delivery over extended periods while enhancing patient comfort, supporting self-administration, and improving overall treatment outcomes.

Analyst Perspective

The global wearable injectors market is expanding rapidly at the intersection of healthcare, biologics, and patient-centric care, driven by a growing prevalence of chronic conditions like cancer, diabetes, and autoimmune diseases alongside an increasing pipeline of high-viscosity, large-volume specialty pharmaceuticals. To lower hospital-based infusion costs and improve patient convenience and compliance, healthcare systems are increasingly adopting these devices to enable controlled, automated, and long-term subcutaneous self-administration at home. Ultimately, wearable injectors bridge the technological limitations of traditional autoinjectors and prefilled syringes, serving as a vital solution for decentralized healthcare and enhanced therapeutic outcomes.

Type Insights

Based on type, the on-body segment led the market with the largest revenue share of 55.2% in 2025, owing to their increased demand as these patches are comfortable to wear on the skin (stomach), are water resistant, and convenient to use at home The benefits associated with on-body wearable injectors include a decrease in the number of hospital visits as it decreases healthcare costs, lifecycle management, flexible dosing, and automatic warming of refrigerated drugs. Medtronic (Ireland) introduced an infusion set in April 2021 that allows for the transport of insulin from the pump to the body for a duration of up to seven days.

The off-body wearable injectors are expected to expand at a CAGR of 16.1% during the forecast period. These devices eliminate risks, such as painful removal of devices, adhesive fitting issues to the skin, and skin sensitivity or irritation. As a result of rising investments in the development of improved off-body, injectors is anticipated to boost the growth of this segment in the future.

Technology Insights

Based on technology, the spring-based segment led the market with the largest revenue share of 36.0% in 2025 and is expected to dominate throughout the forecast period. The market dominance is due to user-friendliness and patients’ ability to precisely distribute the medication subcutaneously by pushing one or more buttons on the device. BD Libertas Wearable Injector is a pre-fillable and innovative drug delivery system offered by BD, a U.S.-based medical device company. It is integrated with a spring-based power source that eliminates the need for batteries or disposal of heavy metals. The rotary pump wearable injectors segment is expected to grow at the fastest CAGR of 15.8% during the forecast period due to their increasing demand as they are more convenient for use.

Application Insights

Based on application, the oncology segment led the market with the largest revenue share of 29.5% in 2025 and is likely to dominate the market owing to the rising prevalence of cancer coupled with an increasing shift toward self-administration of medication among patients. Many drugs are available in the market today; however, to use them, a patient must visit a healthcare center frequently, which leads to increased expenditure and discomfort. The Canadian Cancer Society estimates that in 2022, approximately 13% of Canadians got lung and bronchus cancer, which caused the death of 24% of all cancer patients. Due to the rising incidence of cancer and the tendency toward patients’ self-administering medication is rising.

The rotary pump wearable injectors segment is expected to grow at the fastest CAGR of 15.8% during the forecast period due to their increasing demand as they are more convenient for use. The World Health Organization (WHO) reported that approximately 20 million annual deaths are caused by infectious diseases globally. The prevalence of emerging infectious diseases, which are new or affect more people than before, such as Coronavirus, Ebola, Salmonella, Hepatitis A, and West Nile virus, increases the demand for injectors. The growing need for advanced drug delivery is one of the major factors driving the growth of the global market.

End-use Insights

Based on end use, the homecare segment led the market with the largest revenue share of 42.9% in 2025. The market is growing due to rising demand for home-based healthcare and the requirement of advanced drug delivery devices requiring minimal expertise, and lesser hospitalization of the patients is expected to fuel the demand for wearable injectors globally. The low cost of wearable injectors and the rising demand to cut healthcare expenses is expected to drive the home care segment. According to a study, wearable injectors cost around USD 20 and USD 30, while infusion therapy ranges from USD 200 to USD 1,000 or more.

To learn more about this report, Download Free Sample Report

The hospital segment is expected to expand at a rapid rate owing to the rising prevalence of chronic disorders and the increased footfall of patients in hospitals for treatment.Oncology patients often require frequent administration of medications, which results in the need for regular hospital visits. Specialized clinics are also expanding. On-body injectors connected to cloud data enable physicians to track patient information and monitor drug adherence, which was previously managed during clinic visits. The integrated health model leads to an increase in the frequency of physician-patient interactions.

Regional Insights

North America dominated the wearable injectors market with the largest revenue share of 33.2% in 2025. It is attributed to the rising prevalence of chronic & lifestyle-related diseases and augmented healthcare infrastructure. According to the CDC, about 37 million Americans have diabetes, 90 to 95% of whom have type 2 diabetes. The wearable injectors market in the U.S. held the largest share in the North America region in 2025. 

To learn more about this report, Download Free Sample Report

Asia Pacific is expected to grow at a rapid CAGR of around 15.8% during the forecast period as compared to other regions, which can be attributed to favorable government initiatives for the use of medical devices such as wearable injectors due to increasing geriatric population, increase in healthcare expenditure, and increase in awareness about wearable injectors in this region.

Key Companies & Market Share Insights

The market is fragmented with high competition at the global level as it has the presence of major key players. These players focus on growth strategies, such as new product launches, collaborations, partnerships, operational expansion, mergers & acquisitions, and patient awareness campaigns. In March 2021 Aptar and Noble International announced their collaboration with dne pharma, a pioneer in Northern European addiction treatment, in March 2021, using the innovative Unidose Liquid System developed by Ventizolve, Aptar, and Noble. The collaboration aims to prevent the potentially fatal effects of opioid overdose in Europe as soon as feasible.

In addition, numerous biopharmaceutical companies are seeking a better method of drug delivery of their own biological drugs, for which wearable injectors are a suitable solution. For instance, in January 2023, Tandem Diabetes Care, Inc. announced the acquisition of AMF Medical SA, manufacturer of Sigi Patch Pump. In May 2023, Enable Injections, Inc. collaborated with Viridian Therapeutics, Inc., a U.S.-based biotechnology company.

Key Wearable Injector Companies

The following key companies have been profiled for this study on the wearable injectors market.

• BD

• Johnson & Johnson Services, Inc.

• F. Hoffmann-La Roche Ltd.

• Unilife Corporation

• Steady Med Therapeutics, Inc.

• Amgen Inc.

• Insulet Corporation

• Enable Injections

• West Pharmaceutical Services, Inc.

• CeQur Simplicity

Global Wearable Injectors Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global wearable injectors market report based on type, technology, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • On-body

  • Off-body

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Spring-based

  • Motor-driven

  • Rotary pump

  • Expanding battery

  • Other

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Infectious disease

  • Cardiovascular disease

  • Autoimmune disease

  • Immunodeficiency

  • Others

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Clinics

  • Home care

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

  • U.S.

  • Canada

  • Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

  • Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Middle East & Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

Research Methodology

The wearable injectors market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each wearable injectors segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations